Compare Incyte Corporation (INCY) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Centrus Energy Corp — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Centrus Energy Corp trades at $142.44 (market cap $2.91B). The key difference: Incyte Corporation is far larger — about 7.9× Centrus Energy Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Centrus Energy Corp for 29 Days on average.
| INCY | LEU | |
|---|---|---|
Market Cap | $22.85B | $2.91B |
Volume | 1,927,029 | 903,777 |
Sector | Health | Energy |
52-Week High | $129.93 | $436.00 |
52-Week Low | $83.80 | $138.18 |
Typical Hold Time | 33 Days | 29 Days |
Enterprise Value | $18.35B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Centrus Energy (LEU) trades at $142.09, down 3.43% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings with an EPS beat but faces declining profitability margins year-over-year. Recent news highlights Centrus' strategic position as the sole US-licensed producer of high-assay low-enriched uranium (HALEU), securing multiple supply contracts amid growing nuclear energy demand.
Outlook: LEU offers exposure to the nuclear fuel supply chain with strong analyst support (46% buy ratings) and a $218.10 consensus price target. Key risks include execution challenges, volatile cash flows, and high valuation multiples (P/E 75.18). The stock's near-term performance hinges on operational execution and contract ramp-up.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
